Funding profile · Healthcare IT, medication access
Latent Health
An $80 million Series A announced in March 2026, agreed on by every outlet that covered it, but with no SEC Form D found under the company’s name as of September 2026.
Data as of September 25, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2023 | Y Combinator, Winter 2023 | Not disclosed | Y Combinator | YC data |
| Before Mar 2026 | Seed stage, undisclosed | Not disclosed | Not named in sources found | Not found |
| Mar 2026 | Series A | $80.0M announced | Co-led by Spark Capital and Transformation Capital; Conviction, General Catalyst, Y Combinator participating. MobiHealthNews and The SaaS News also name McKesson Ventures; Latent’s own release folds that name into “and others.” | Press reports + company release |
What the filings show
No SEC Form D notice was found for this company under the names Latent Health, Latent Inc or Latent Technologies. An EDGAR company search for filers named “Latent” that filed Form D returns two companies, Latent Knowledge Solutions Inc. of Connecticut and Latent Labs Technologies, Inc. of Delaware, neither of which mentions healthcare, pharmacy or prior authorization. A separate single-purpose entity, FW Latent Defense Seed Apr 2026, a Series of CGF2021 LLC, filed a Form D in April 2026 but its name points to a defense-related deal, not to this company. None of these filers can be tied to Latent Health on the evidence gathered here.
That does not mean no capital moved. Companies raising under Section 4(a)(2), or a round still inside the 15 day Form D filing window, would not yet appear on EDGAR. It means only that, as of this page’s research date, the $80 million round rests entirely on the company’s own announcement and on press coverage that repeats the same figure, not on a federal filing.
Reading the record
- Every outlet agrees on the headline number.Forbes, MobiHealthNews, The SaaS News, Pulse 2.0 and American Kahani all reported $80 million, co-led by Spark Capital and Transformation Capital, within about a week of each other in March 2026. That kind of agreement across independently reported outlets is unusual for a private round and suggests the figure came from a common press packet, not that it is unverified.
- The investor list is not identical everywhere.MobiHealthNews and The SaaS News name McKesson Ventures as a participant. Latent’s own press release lists “Transformation Capital, Spark Capital, Conviction, General Catalyst, Y Combinator, and others” and does not name McKesson Ventures. McKesson owns CoverMyMeds, which announced a product partnership with Latent around the same period, so a McKesson Ventures check would fit the commercial relationship, but the company’s own materials do not confirm it by name.
- Valuation and revenue rest on one anonymous source.The approximately $600 million valuation and the more than $20 million in annualized revenue both come from Forbes, the valuation attributed to “a person familiar with the deal” and the revenue figure stated without a named source. No other outlet in this research independently reproduced either number.
- No Form D means no independent confirmation of deal mechanics.Without a filing, there is no public record of how much was actually sold versus offered, how many investors participated, or who holds board seats. Everything in the rounds table above is a reported or company-stated figure, not a filed one.
- The company’s paper trail before the Series A is thin.Latent went through YC’s Winter 2023 batch and had grown to four health system customers by the time it engaged Ochsner Health as a design partner in November 2023, implying an earlier seed round, but no source found here discloses its size or investors.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Health system growth | Four customers as of late 2023, more than 45 by March 2026, more than 60 per the company’s site in September 2026. | Company-stated |
| Named enterprise customer | Ochsner Health, design partner since November 2023, moved to a three year enterprise agreement in June 2025 covering specialty, infusion and retail pharmacy workflows. | Independent reporting |
| Reported outcomes at Ochsner | 4 to 5 minute prior authorization reviews, 75 percent faster than industry benchmark; more than 20,000 patients affected in 2024; a 96 percent increase in monthly throughput per staff member. | Independent reporting |
| Integration partner | CoverMyMeds, McKesson’s prior authorization network, announced a combined offering with Latent, described on CoverMyMeds’ own site. | Partner-stated |
| Accelerator | Y Combinator, Winter 2023 batch, team of 50 per YC’s company page. | Public record |
What to watch
- A Form D filing tied to Latent Health, Latent Inc, or another confirmable corporate name for the company.
- Whether McKesson Ventures is confirmed or denied as a Series A participant.
- Named revenue or customer figures with a source other than the company itself.
- A disclosed size for the seed round that preceded the Series A.
The Latent Health story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- IndependentThis $600 Million AI Startup Is Speeding Up Paperwork So Patients Get Drugs Faster
- IndependentLatent raises $80M for AI medication approval platform
- IndependentLatent Raises $80 Million in Series A
- IndependentLatent Health: $80 Million Raised For Clinical AI Platform Advancing Medication Access
- IndependentHow Indian American Founders of Latent Health Are Using AI to Get Life-Saving Medications to Patients Faster
- IndependentOchsner Health expands AI partnership for faster meds
- PartnerOchsner Health partners with Latent for AI-driven medication access
- CompanyLatent emerges as clinical AI leader, raising $80M to close the gap between diagnosis and treatment
- Public recordLatent company profile, Y Combinator
- Public recordEDGAR company search for Form D filers named Latent
Compiled from SEC EDGAR records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; no such notice was found for this company. Healthcare Venture Capital Fund holds no position in Latent Health. This page is not an offer to sell or a recommendation to buy any security.